Effect of SCH 23390 on (+/-)-3,4-methylenedioxymethamphetamine hyperactivity and self-administration in rats
Daniela E, Brennan K, Gittings D, Hely L, Schenk S.
School of Psychology,
Victoria University of Wellington,
P.O. Box 600, Wellington, New Zealand.
Pharmacol Biochem Behav. 2004 Apr;77(4):745-50


Recently, we demonstrated that (+/-)-3,4-methylenedioxymethamphetamine (MDMA; ecstasy) was reliably and dose-dependently self-administered by previously drug-naive laboratory rats. The neurochemical basis of MDMA self-administration has not, however, been extensively studied. The present study investigated the role of dopamine in MDMA self-administration and hyperactivity. Pretreatment with the D1-like antagonist, SCH 23390 (0.01-0.08 mg/kg) produced a dose-dependent attenuation of MDMA (20.0 mg/kg)-produced hyperactivity. In self-administration tests, the baseline rate of responding maintained by intravenous infusions varied inversely with MDMA dose; as the dose available was changed, responding also changed so that about 10.0 mg/kg MDMA was self-administered during each daily 2-h session. Pretreatment with SCH 23390 (0.02 mg/kg) produced a rightward shift in the MDMA dose-response curve. These findings suggest that MDMA self-administration, like self-administration of other drugs of abuse, is dependent on the activation of dopaminergic substrates.

Protect and survive
MDMA and immunity
MDMA and dopamine
Mesolimbic dopamine
Dopaminergic damage
MDMA and serotonin synthesis
MDMA, serotonin and dopamine
Potentiation of dopamine release
Haloperidol pretreatment: effects
Ecstasy and dopamine neurons: risks?

and further reading

Future Opioids
BLTC Research
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family